A study to assess the tolerability of ianalumab (VAY736)

A study to assess the tolerability of ianalumab (VAY736) with investigator’s choice thrombopoietin receptor agonist (IC TPO-RA) in patients with primary immune thrombocytopenia (ITP)

Protocol# CVAY736Q1US01

Learn More

Principal Investigator(s)

Joshua R. Dower, MD

Sponsor(s)
Novartis Pharmaceuticals

Location

Bennett Cancer Center

One Hospital Plaza
Stamford, CT 06902
Main: 203-358-8879

Our website uses cookies

This website uses cookies to give you the very best experience. Your continued use of this site is considered permission by you to use cookies in this manner. Please review our Privacy Policy and Terms of Use for more information about the data we collect and the types of cookies we use. Please note, if you link off our website to a 3rd party site of any kind, that website has its own terms and conditions.

ACCEPT AND CLOSE

A study to assess the tolerability of ianalumab (VAY736)